Abstract
Further development of clinical models of dementia to augment present unsatisfactory animal models, is of central importance to the understanding of the neurochemistry of dementia. Furthermore, present definitions of the neurotoxic processes underlying dementing disorders will need to be improved. Routine clinical markers will be necessary for the development of any therapy beyond present attempts for symptomatic treatment with neurotransmitter replacement.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call